Patents by Inventor Bruce H. KenKnight
Bruce H. KenKnight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108901Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. Between titration sessions one or more parameters, such as, for example, an acclimation interval, may be adjusted based on the patient's response to the stimulation. This personalized titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: ApplicationFiled: December 15, 2023Publication date: April 4, 2024Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. KenKnight, Badri Amurthur, Scott R. Stubbs
-
Patent number: 11931583Abstract: A neurostimulation system comprises a control system configured to monitor a patient receiving neurostimulation therapy. The neurostimulation therapy has a stimulation cycle comprising a stimulation ON period, in which the patient is receiving neurostimulation, and a stimulation OFF period, in which the patient is not receiving neurostimulation. The control system is programmed to receive electrocardiogram (ECG) data from the patient receiving the neurostimulation therapy. The control system is further programmed to monitor a heart rate of the patient based on the ECG data over at least one stimulation cycle of the neurostimulation therapy. The control system is further programmed to generate an indication of signal stability to be displayed to a user based on the received ECG data.Type: GrantFiled: October 4, 2021Date of Patent: March 19, 2024Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Scott R. Stubbs, Bruce H. KenKnight, Scott Mazar, Badri Amurthur
-
Patent number: 11918812Abstract: Systems and methods are provided for delivering vagus nerve stimulation and carotid baroreceptor stimulation to patients for treating chronic heart failure and hypertension. The vagus nerve stimulation and carotid baroreceptor stimulation therapies may be provided using a single implantable pulse generator, which can coordinate delivery of the therapies.Type: GrantFiled: April 21, 2020Date of Patent: March 5, 2024Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. Kenknight, Badri Amurthur
-
Patent number: 11918813Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. This titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: GrantFiled: November 29, 2021Date of Patent: March 5, 2024Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. KenKnight, Badri Amurthur
-
Patent number: 11878159Abstract: An implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction is provided. A stimulation therapy lead includes helical electrodes configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins electrically connected to the helical electrodes. A neurostimulator includes an electrical receptacle into which the connector pins are securely and electrically coupled. The neurostimulator also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes in alternating cycles of stimuli application and stimuli inhibition that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials.Type: GrantFiled: May 24, 2021Date of Patent: January 23, 2024Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Badri Amurthur, Bruce H. Kenknight
-
Patent number: 11865344Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. Between titration sessions one or more parameters, such as, for example, an acclimation interval, may be adjusted based on the patient's response to the stimulation. This personalized titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: GrantFiled: December 5, 2019Date of Patent: January 9, 2024Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. KenKnight, Badri Amurthur, Scott R. Stubbs
-
Publication number: 20230398358Abstract: A method of neurostimulation titration includes titrating a neurostimulation signal from a first set of parameters toward a target set of parameters according to a titration aggressiveness profile having a titration hold point. The method further includes receiving a hold indicator indicating that the titration has reached the titration hold point. The method further includes initiating an intermediate hold of the titrating of the neurostimulation signal in response to receiving the hold indicator. The method further includes receiving an indication of a titration resumption that discontinues the intermediate hold.Type: ApplicationFiled: August 15, 2023Publication date: December 14, 2023Applicant: LivaNova USA, Inc.Inventors: Scott Stubbs, Imad Libbus, Scott Mazar, Bruce H. KenKnight, Badri Amurthur
-
Patent number: 11745015Abstract: A method of neurostimulation titration. The method includes setting titration parameters for an electrical signal delivered by an implantable medical device, initiating titration with the titration parameters and an aggressiveness profile, performing titration by increasing at least one of a current amplitude, a frequency, a pulse width or a duty cycle of the electrical signal until a threshold is reached or a side effect is detected, pausing the titration while waiting for commands from the patient or caregiver, and resuming the titration in response to receiving authorization from an external device.Type: GrantFiled: October 15, 2021Date of Patent: September 5, 2023Assignee: LivaNova USA, Inc.Inventors: Scott Stubbs, Imad Libbus, Scott Mazar, Bruce H. KenKnight, Badri Amurthur
-
Patent number: 11738199Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. This neural fulcrum zone corresponds to a combination of stimulation parameters at which autonomic engagement is achieved, while the tachycardia-inducing stimulation effects are offset by the bradycardia-inducing effects, thereby minimizing side effects such as significant heart rate changes while providing a therapeutic level of stimulation.Type: GrantFiled: July 30, 2021Date of Patent: August 29, 2023Assignees: LivaNova USA, Inc., East Tennessee State UniversityInventors: Bruce H. KenKnight, Jeffrey L. Ardell, Imad Libbus, Badri Amurthur
-
Publication number: 20230146182Abstract: An implantable vagus nerve stimulation (VNS) system includes a sensor configured to measure ECG data for a patient, a stimulation subsystem configured to deliver VNS to the patient, and a control system configured to perform a heart rate variability analysis with the ECG data. In some aspects, performing the heart rate variability analysis includes measuring R-R intervals between successive R-waves for the ECG data measured during a stimulation period of VNS therapy and a baseline period of the VNS therapy, wherein the stimulation period comprises at least a portion of the ON period and the baseline period comprises at least a portion of the OFF period immediately preceding the ON period, and generating a plot of each R-R interval against an immediately successive R-R interval for each of the stimulation period and the baseline period configured to be displayed on a display.Type: ApplicationFiled: January 3, 2023Publication date: May 11, 2023Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce D. Nearing, Badri Amurthur, Bruce H. KenKnight, Richard L. Verrier
-
Publication number: 20230106472Abstract: A neurostimulation system comprises a control system configured to monitor a patient receiving neurostimulation therapy. The neurostimulation therapy has a stimulation cycle comprising a stimulation ON period, in which the patient is receiving neurostimulation, and a stimulation OFF period, in which the patient is not receiving neurostimulation. The control system is programmed to receive electrocardiogram (ECG) data from the patient receiving the neurostimulation therapy. The control system is further programmed to monitor a heart rate of the patient based on the ECG data over at least one stimulation cycle of the neurostimulation therapy. The control system is further programmed to generate an indication of signal stability to be displayed to a user based on the received ECG data.Type: ApplicationFiled: October 4, 2021Publication date: April 6, 2023Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Scott R. Stubbs, Bruce H. KenKnight, Scott Mazar, Badri Amurthur
-
Patent number: 11612749Abstract: A method for assessing a patient's suitability for receiving a vagus nerve stimulation therapy includes receiving a criterion regarding the patient's suitability for receiving a vagus nerve stimulation therapy; controlling a stimulation device to provide stimulation to a vagus nerve of the patient; receiving, from a sensor, response data indicative of a physiological response of the patient to the stimulation of the vagus nerve; and determining the patient's suitability for receiving the vagus nerve stimulation therapy based on the criterion and the physiological response of the patient to the stimulation.Type: GrantFiled: March 31, 2017Date of Patent: March 28, 2023Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. Kenknight, Christine Henry
-
Patent number: 11554263Abstract: An implantable vagus nerve stimulation (VNS) system includes a sensor configured to measure ECG data for a patient, a stimulation subsystem configured to deliver VNS to the patient, and a control system configured to perform a heart rate variability analysis with the ECG data. In some aspects, performing the heart rate variability analysis includes measuring R-R intervals between successive R-waves for the ECG data measured during a stimulation period and a baseline period, plotting each R-R interval against an immediately preceding R-R interval for each of the stimulation period and the baseline period, and determining at least one of a standard deviation from an axis of a line perpendicular to an identity line for each of the stimulation period plot and the baseline period plot or a centroid of each of the stimulation period plot and the baseline period plot.Type: GrantFiled: May 24, 2019Date of Patent: January 17, 2023Assignee: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce D. Nearing, Badri Amurthur, Bruce H. KenKnight, Richard L. Verrier
-
Publication number: 20220226657Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. The implanted stimulation device includes a physiological sensor for monitoring the patient's response to the neurostimulation therapy on an ambulatory basis over extended periods of time and a control system for adjusting stimulation parameters to maintain stimulation in the neural fulcrum zone based on detected changes in the physiological response to stimulation.Type: ApplicationFiled: April 8, 2022Publication date: July 21, 2022Applicants: LivaNova USA, Inc., East Tennessee State UniversityInventors: Imad Libbus, Badri Amurthur, Bruce H. KenKnight, Jeffrey L. Ardell
-
Publication number: 20220118250Abstract: A method for managing bradycardia through vagus nerve stimulation is provided. An implantable neurostimulator configured to deliver electrical therapeutic stimulation in both afferent and efferent directions of a patient's cervical vagus nerve is provided. An operating mode is stored, which includes parametrically defining a maintenance dose of the electrical therapeutic stimulation tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses. The maintenance dose is delivered via a pulse generator through a pair of helical electrodes via an electrically coupled nerve stimulation therapy lead independent of cardiac cycle. The patient's physiology is monitored, and upon sensing a condition indicative of bradycardia, the delivery of the maintenance dose is suspended.Type: ApplicationFiled: September 27, 2021Publication date: April 21, 2022Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Badri Amurthur, Bruce H. KenKnight
-
Patent number: 11298543Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. The implanted stimulation device includes a physiological sensor for monitoring the patient's response to the neurostimulation therapy on an ambulatory basis over extended periods of time and a control system for adjusting stimulation parameters to maintain stimulation in the neural fulcrum zone based on detected changes in the physiological response to stimulation.Type: GrantFiled: December 27, 2018Date of Patent: April 12, 2022Assignees: LivaNova USA, Inc., East Tennessee State UniversityInventors: Imad Libbus, Badri Amurthur, Bruce H. KenKnight, Jeffrey L. Ardell
-
Publication number: 20220105347Abstract: A method of neurostimulation titration. The method includes setting titration parameters for an electrical signal delivered by an implantable medical device, initiating titration with the titration parameters and an aggressiveness profile, performing titration by increasing at least one of a current amplitude, a frequency, a pulse width or a duty cycle of the electrical signal until a threshold is reached or a side effect is detected, pausing the titration while waiting for commands from the patient or caregiver, and resuming the titration in response to receiving authorization from an external device.Type: ApplicationFiled: October 15, 2021Publication date: April 7, 2022Applicant: LivaNova USA, Inc.Inventors: Scott Stubbs, Imad Libbus, Scott Mazar, Bruce H. KenKnight, Badri Amurthur
-
Publication number: 20220080207Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. This titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.Type: ApplicationFiled: November 29, 2021Publication date: March 17, 2022Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Bruce H. KenKnight, Badri Amurthur
-
Publication number: 20220016429Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. This neural fulcrum zone corresponds to a combination of stimulation parameters at which autonomic engagement is achieved, while the tachycardia-inducing stimulation effects are offset by the bradycardia-inducing effects, thereby minimizing side effects such as significant heart rate changes while providing a therapeutic level of stimulation.Type: ApplicationFiled: July 30, 2021Publication date: January 20, 2022Applicants: LivaNova USA, Inc., EAST TENNESSEE STATE UNIVERSITYInventors: Bruce H. KenKnight, Jeffrey L. Ardell, Imad Libbus, Badri Amurthur
-
Publication number: 20220016428Abstract: An implantable neurostimulator-implemented method for managing tachyarrhythmias through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator, is configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers of a patient's cervical vagus nerve. Operating modes of the pulse generator are stored. A maintenance dose of the electrical therapeutic stimulation is delivered to the vagus nerve via the pulse generator to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses. A restorative dose of the electrical therapeutic stimulation is delivered to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity than the maintenance dose.Type: ApplicationFiled: July 29, 2021Publication date: January 20, 2022Applicant: LivaNova USA, Inc.Inventors: Imad Libbus, Badri Amurthur, Bruce H. KenKnight